Spying on HIV with SPR

Trends in Microbiology

Volumn 11, Issue 3, 2003, Pages 124-133

  Rich, Rebecca L ^a   Myszka, David G ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOHYDRATE; NUCLEIC ACID; PROTEIN;

BIOSENSOR; EPITOPE MAPPING; HUMAN IMMUNODEFICIENCY VIRUS; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SURFACE PLASMON RESONANCE; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; RNA VIRUSES;

EID: 0037342411     PISSN: 0966842X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0966-842X(03)00025-8     Document Type: Review

References (107)

1. Myszka D.G., Rich R.L. Implementing surface plasmon resonance biosensors in drug discovery. Pharm. Sci. Technol. Today. 3:2000;310-317.
2. Homola J., et al. Surface plasmon resonance biosensors. Ligler F.S., Rowe Taitt C.A., et al. Optical Biosensors: Present and Future. 2002;207-251 Elsevier Science.
3. Fägerstam L.G., et al. Detection of antigen-antibody interactions by surface plasmon resonance. Application to epitope mapping. J. Mol. Recog. 3:1990;208-214.
4. Malmqvist M. Biospecific interaction analysis using biosensor technology. Nature. 361:1993;186-187.
5. Malmqvist M. Epitope mapping by label-free biomolecular interaction analysis. Methods. 9:1996;525-532.
6. Chen Y.H., et al. Antibodies against human IFN-alpha and -beta recognized the immunosuppressive domain of HIV-1 gp41 and inhibit gp41-binding to the putative cellular receptor protein p45. Immunol. Lett. 69:1999;253-257.
7. Coëffier E., et al. Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein. Vaccine. 19:2000;684-693.
8. Ferrer M., et al. Structural and functional characterization of an epitope in the conserved C-terminal region of HIV-1 gp120. J. Pept. Res. 54:1999;32-42.
9. Kröpelin M., et al. Inhibition of HIV-1 gp120 binding to CD4 + T cells by monoclonal antibodies directed against the gp120 C1 or C4 region. Immunol. Lett. 63:1998;19-25.
10. Sugiura W., et al. Characterization of conformation-dependent anti-gp120 murine monoclonal antibodies produced by immunization with monomeric and oligomeric human immunodeficiency virus type 1 envelope proteins. Virology. 254:1999;257-267.
11. De Rocquigny H., et al. Generation of monoclonal antibodies specifically directed against the proximal zinc finger of HIV type 1 NCp7. AIDS Res. Hum. Retroviruses. 16:2000;1259-1267.
12. Tanchou V., et al. Conformational changes between human immunodeficiency virus type 1 nucleocapsid protein NCp7 and its precursor NCp15 as detected by anti-NCp7 monoclonal antibodies. J. Gen. Virol. 76:1995;2457-2466.
13. Tanchou V., et al. Monoclonal antibody-mediated inhibition of RNA binding and annealing activities of HIV type 1 nucleocapsid protein. AIDS Res. Hum. Retroviruses. 10:1994;983-993.
14. Ohba H., et al. An immunodominant neutralization epitope on the 'thumb' subdomain of human immunodeficiency virus type 1 reverse transcriptase revealed by phage display antibodies. J. Gen. Virol. 82:2001;813-820.
15. Yi J., et al. Mapping the epitope of an inhibitory monoclonal antibody to the C-terminal DNA-binding domain of HIV-1 integrase. J. Biol. Chem. 277:2002;12164-12174.
16. Karlsson R., et al. Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system. J. Immunol. Methods. 145:1991;229-240.
17. Karlsson R. Real-time competitive kinetic analysis of interactions between low-molecular-weight ligands in solution and surface-immobilized receptors. Anal. Biochem. 221:1994;142-151.
18. Glaser R.W., Hausdorf G. Binding kinetics of an antibody against HIV p24 core protein measured with real-time biomolecular interaction analysis suggest a slow conformational change in antigen p24. J. Immunol. Methods. 189:1996;1-14.
19. Roos H., et al. Thermodynamic analysis of protein interactions with biosensor technology. J. Mol. Recog. 11:1998;204-210.
20. de Haard J.J., et al. Selection of human anti-human immunodeficiency virus type 1 envelope single-chain antibodies from a peripheral blood cell-based phage repertoire. J. Gen. Virol. 79:1998;2883-2894.
21. Zeder-Lutz G., et al. Differential recognition of epitopes present on monomeric and oligomeric forms of gp160 glycoprotein of human immunodeficiency virus type 1 by human monoclonal antibodies. Eur. J. Biochem. 268:2001;2856-2866.
22. Ditzel H.J., et al. Neutralizing recombinant human antibodies to a conformational V2- and CD4-binding site-sensitive epitope of HIV-1 gp120 isolated by using an epitope-masking procedure. J. Immunol. 154:1995;893-906.
23. Parren P.W., et al. Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity. J. Virol. 72:1998;3512-3519.
24. Zhang W., et al. Conformational changes of gp120 in epitopes near the CCR5 binding site are induced by CD4 and a CD4 miniprotein mimetic. Biochemistry. 38:1999;9405-9416.
25. Zhang W., et al. Antibody 17b binding at the coreceptor site weakens the kinetics of the interaction of envelope glycoprotein gp120 with CD4. Biochemistry. 40:2001;1662-1670.
26. Cleveland S.M., et al. Properties of a neutralizing antibody that recognizes a conformational form of epitope ERDRD in the gp41 C-terminal tail of human immunodeficiency virus type 1. J. Gen. Virol. 81:2000;1251-1260.
27. Mani J.C., et al. Effect of HIV-1 peptide presentation on the affinity constants of two monoclonal antibodies determined by BIAcore technology. Mol. Immunol. 31:1994;439-444.
28. Callebaut C., et al. Identification of V3 loop-binding proteins as potential receptors implicated in the binding of HIV particles to CD4(+) cells. J. Biol. Chem. 273:1998;21988-21997.
29. Gorny M.K., et al. Human monoclonal antibodies to the V3 loop of HIV-1 with intra- and interclade cross-reactivity. J. Immunol. 159:1997;5114-5122.
30. Ota A., et al. Cross-reactivity of anti-HIV-1-p17-derivative peptide (P30-52) antibody to Env V3 peptide. Hybridoma. 18:1999;149-157.
31. Wu G., et al. The binding of a glycoprotein 120 V3 loop peptide to HIV-1 neutralizing antibodies. Structural implications. J. Biol. Chem. 275:2000;36645-36652.
32. Thompson J., et al. Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: use of phage display to improve affinity and broaden strain reactivity. J. Mol. Biol. 256:1996;77-88.
33. Ota A., Ueda S. Evaluation of the affinity measurement of anti-HIV-1 p17 monoclonal antibody by BIAcore. Hybridoma. 17:1998;471-477.
34. Astoul C.H., et al. Accessibility of the high-mannose glycans of glycoprotein gp120 from human immunodeficiency virus type 1 probed by in vitro interaction with mannose-binding lectins. Biochem. Biophys. Res. Commun. 274:2000;455-460.
35. Bracci L., et al. Molecular mimicry between the rabies virus glycoprotein and human immunodeficiency virus-1 GP120: cross-reacting antibodies induced by rabies vaccination. Blood. 90:1997;3623-3628.
36. Brigham-Burke M., et al. Detection of receptor-ligand interactions using surface plasmon resonance: model studies employing the HIV-1 gp120/CD4 interaction. Anal. Biochem. 205:1992;125-131.
37. Chen Y.H., et al. The C domain of HIV-1 gp41 binds the putative cellular receptor protein P62. AIDS. 13:1999;1021-1024.
38. Moulard M., et al. Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120. J. Virol. 74:2000;1948-1960.
39. Myszka D.G., et al. Energetics of the HIV gp120-CD4 binding reaction. Proc. Natl. Acad. Sci. U. S. A. 97:2000;9026-9031.
40. Wu H., et al. Kinetic and structural analysis of mutant CD4 receptors that are defective in HIV gp120 binding. Proc. Natl. Acad. Sci. U. S. A. 93:1996;15030-15035.
41. Xiao Y., et al. HIV-1 gp41 by N-domain binds the potential receptor protein P45. Int. Arch. Allergy Immunol. 121:2000;253-257.
42. Zhang C.W.-H., et al. Expression, purification, and characterization of recombinant HIV gp140. J. Biol. Chem. 276:2001;39577-39585.
43. Chen Y.H., et al. HIV-2 transmembrane protein gp36 binds to the putative cellular receptor proteins P45 and P62. Immunobiology. 201:2000;317-322.
44. Yang H., et al. Characterization of interaction between C-domain on HIV-1 gp41 and the putative receptor protein p62. Immunobiology. 203:2001;778-785.
45. Wyss S., et al. The highly conserved C-terminal dileucine motif in the cytosolic domain of the human immunodeficiency virus type 1 envelope glycoprotein is critical for its association with the AP-1 clathrin adaptor. J. Virol. 75:2001;2982-2992.
46. Cormier E.G., et al. Specific interaction of CCR5 amino-terminal domain peptides containing sulfotyrosines with HIV-1 envelope glycoprotein gp120. Proc. Natl. Acad. Sci. U. S. A. 97:2000;5762-5767.
47. Cormier E.G., et al. Mapping the determinants of the CCR5 amino-terminal sulfopeptide interaction with soluble human immunodeficiency virus type 1 gp120-CD4 complexes. J. Virol. 75:2001;5541-5549.
48. Hoffman T.L., et al. A biosensor assay for studying ligand-membrane receptor interactions: binding of antibodies and HIV-1 Env to chemokine receptors. Proc. Natl. Acad. Sci. U. S. A. 97:2000;11215-11220.
49. Misumi S., et al. A cyclic dodecapeptide-multiple-antigen peptide conjugate from the undecapeptidyl arch (from Arg(168) to Cys(178)) of extracellular loop 2 in CCR5 as a novel human immunodeficiency virus type 1 vaccine. J. Virol. 75:2001;11614-11620.
50. Stenlund, P. et al. Capture and reconstitution of G protein-coupled receptors on a biosensor surface. Anal. Biochem. (in press).
51. Lin S., et al. Characterization of the 'helix clamp' motif of HIV-1 reverse transcriptase using MALDI-TOF MS and surface plasmon resonance. Anal. Chem. 72:2000;2635-2640.
52. Gorshkova I.I., et al. HIV-1 reverse transcriptase interaction with model RNA-DNA duplexes. Anal. Biochem. 291:2001;198-206.
53. Druillennec S., et al. Evidence of interactions between the nucleocapsid protein NCp7 and the reverse transcriptase of HIV-1. J. Biol. Chem. 274:1999;11283-11288.
54. Kim S.J., et al. Selection and stabilization of the RNA aptamers against the human immunodeficiency virus type-1 nucleocapsid protein. Biochem. Biophys. Res. Commun. 291:2002;925-931.
55. Frankel A.D., Young J.A. HIV-1: fifteen proteins and an RNA. Annu. Rev. Biochem. 67:1998;1-25.
56. Yi J., et al. Divalent cations stimulate preferential recognition of a viral DNA end by HIV-1 integrase. Biochemistry. 38:1999;8458-8468.
57. 2+. J. Inorg. Biochem. 82:2000;197-206.
58. Rusnati M., et al. Pentosan polysulfate as an inhibitor of extracellular HIV-1 Tat. J. Biol. Chem. 276:2001;22420-22425.
59. Chapman R.L., et al. Small molecule modulators of HIV Rev/Rev response element interaction identified by random screening. Antiviral Res. 54:2002;149-162.
60. Hendrix M., et al. Direct observation of aminoglycoside-RNA interactions by surface plasmon resonance. J. Am. Chem. Soc. 119:1997;3641-3648.
61. Van Ryk D.I., Venkatesan S. Real-time kinetics of HIV-1 Rev-Rev response element interactions. J. Biol. Chem. 274:1999;17452-17463.
62. West M.L., Ramsdale T.E. Binding kinetics and bioassay of RRE mRNA fragments to a peptide containing the recognition domain of HIV-1 Rev. Biomed. Pept. Proteins Nucleic Acids. 2:1996;85-88.
63. Galio L., et al. Analysis of interactions between huGATA-3 transcription factor and three GATA regulatory elements of HIV-1 long terminal repeat, by surface plasmon resonance. Anal. Biochem. 253:1997;70-77.
64. Mischiati C., et al. Interaction of the human NF-κB p52 transcription factor with DNA-PNA hybrids mimicking the NF-κB binding sites of the human immunodeficiency virus type 1 promoter. J. Biol. Chem. 274:1999;33114-33122.
65. Galio L., et al. Real-time study of interactions between a composite DNA regulatory region (HIV-1 LTR NRE) and several transcription factors of nuclear extracts. Biochem. Biophys. Res. Commun. 264:1999;6-13.
66. Darfeuille F., et al. 2′-O-methyl-RNA hairpins generate loop-loop complexes and selectively inhibit HIV-1 Tat-mediated transcription. Biochemistry. 41:2002;12186-12192.
67. Darfeuille F., et al. Loop-loop interaction of HIV-1 TAR RNA with N3′→P5′ deoxyphosphoramidate aptamers inhibits in vitro Tat-mediated transcription. Proc. Natl. Acad. Sci. U. S. A. 99:2002;9709-9714.
68. Duconge F., et al. Is a closing 'GA pair' a rule for stable loop-loop RNA complexes? J. Biol. Chem. 275:2000;21287-21294.
69. Nair T.M., et al. Surface plasmon resonance kinetic studies of the HIV TAR RNA kissing hairpin complex and its stabilization by 2-thiouridine modification. Nucleic Acids Res. 28:2000;1935-1940.
70. Waysbort A., et al. Pyrimidine tract binding protein and La autoantigen interact differently with the 5′ untranslated regions of lentiviruses and oncoretrovirus mRNAs. FEBS Lett. 490:2001;54-58.
71. Bianchi N., et al. Biosensor technology and surface plasmon resonance for real-time detection of HIV-1 genomic sequences amplified by polymerase chain reaction. Clin. Diagn. Virol. 8:1997;199-208.
72. Garrus J.E., et al. Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell. 107:2001;55-65.
73. Pornillos O., et al. Structure and functional interactions of the Tsg101 UEV domain. EMBO J. 21:2002;2397-2406.
74. Fisher R.J., et al. Sequence-specific binding of human immunodeficiency virus type 1 nucleocapsid protein to short oligonucleotides. J. Virol. 72:1998;1902-1909.
75. Flamminio G., et al. Aspects of molecular interaction between HIV p17 and human γ interferon. AIDS Res. Hum. Retroviruses. 11:1995;1441-1447.
76. Schramm H.J., et al. The inhibition of human immunodeficiency virus proteases by 'interface peptides'. Antiviral Res. 30:1996;155-170.
77. Yoo S., et al. Molecular recognition in the HIV-1 capsid/cyclophilin A complex. J. Mol. Biol. 269:1997;780-795.
78. Lee C.H., et al. A single amino acid in the SH3 domain of Hck determines its high affinity and specificity in binding to HIV-1 Nef protein. EMBO J. 14:1995;5006-5015.
79. Manninen A., et al. SH3-domain binding function of HIV-1 Nef is required for association with a PAK-related kinase. Virology. 250:1998;273-282.
80. Moarefi I., et al. Activation of the Src-family tyrosine kinase Hck by SH3 domain displacement. Nature. 385:1997;650-653.
81. De Rocquigny H., et al. Interactions of the C-terminus of viral protein R with nucleic acids are modulated by its N-terminus. Eur. J. Biochem. 267:2000;3654-3660.
82. Jacotot E., et al. The HIV-1 viral protein R induces apoptosis via a direct effect on the mitochondrial permeability transition pore. J. Exp. Med. 191:2000;33-45.
83. Jacotot E., et al. Control of mitochondrial membrane permeabilization by adenine nucleotide translocator interacting with HIV-1 viral protein rR and Bcl-2. J. Exp. Med. 193:2001;509-519.
84. Jenkins Y., et al. Biochemical analyses of the interactions between human immunodeficiency virus type 1 Vpr and p6(Gag). J. Virol. 75:2001;10537-10542.
85. VanCott T.C., et al. Characterization of a soluble, oligomeric HIV-1 gp160 protein as a potential immunogen. J. Immunol. Methods. 183:1995;103-117.
86. Richalet-Sécordel P.M., et al. Cross-reactivity of monoclonal antibodies to a chimeric V3 peptide of HIV-1 with peptide analogues studied by biosensor technology and ELISA. J. Immunol. Methods. 176:1994;221-234.
87. de Haard J.J., et al. Selection of recombinant, library-derived antibody fragments against p24 for human immunodeficiency virus type 1 diagnostics. Clin. Diagn. Virol. 5:1998;636-644.
88. Pincus S., et al. Vaccine-specific antibody responses induced by HIV-1 envelope subunit vaccines. J. Immunol. 158:1997;3511-3520.
89. Vancott T.C., et al. Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1. AIDS Res. Hum. Retroviruses. 11:1995;1379-1391.
90. VanCott T.C., et al. Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160. J. Virol. 71:1997;4319-4330.
91. Fischer P.B., et al. The alpha-glucosidase inhibitor N-butyldeoxynojirimycin inhibits human immunodeficiency virus entry at the level of post-CD4 binding. J. Virol. 69:1995;5791-5797.
92. Jin B.S., et al. Design of a peptide inhibitor that blocks the cell fusion mediated by glycoprotein 41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses. 16:2000;1797-1804.
93. Chaiken I. Revealing and utilizing receptor recognition mechanisms in a high-throughput world. J. Cell. Biochem. (Suppl. 37):2001;126-135.
94. Sönksen C., et al. Capture and analysis of low molecular weight ligands by surface plasmon resonance combined with mass spectrometry. J. Mass Spectrom. 7:2001;385-391.
95. Cherepanov P., et al. Mode of interaction of G-quartets with the integrase of human immunodeficiency virus type 1. Mol. Pharmacol. 52:1997;771-780.
96. Alterman M., et al. P1/P1( modified HIV protease inhibitors as tools in two new sensitive surface plasmon resonance biosensor screening assays. Eur. J. Pharm. Sci. 13:2001;203-212.
97. Hämäläinen M.D., et al. Characterization of a set of HIV-1 protease inhibitors using binding kinetics data from a biosensor-based screen. J. Biomol. Screen. 5:2000;353-360.
98. Markgren P.-O., et al. Screening of compounds interacting with HIV-1 proteinase using optical biosensor technology. Anal. Biochem. 265:1998;340-350.
99. Markgren P.-O., et al. Kinetic analysis of the interaction between HIV-1 protease and inhibitors using optical biosensor technology. Anal. Biochem. 279:2000;71-78.
100. Markgren P.-O., et al. Determination of interaction kinetic constants for HIV-1 protease inhibitors using optical biosensor technology. Anal. Biochem. 291:2001;207-218.
101. Markgren P.-O., et al. Relationships between structure and interaction kinetics for HIV-1 proteinase inhibitors. J. Med. Chem. 45:2002;5430-5439.
102. Li K., et al. A heterocyclic inhibitor of the REV-RRE complex binds to RRE as a dimer. Biochemistry. 40:2001;1150-1158.
103. Gambari R., et al. Biospecific interaction analysis (BIA) of low-molecular weight DNA-binding drugs. J. Pharmacol. Exp. Ther. 294:2000;370-377.
104. Esté J.A., et al. Human immunodeficiency virus glycoprotein gp120 as the primary target for the antiviral action of AR177 (Zintevir). Mol. Pharmacol. 53:1998;340-345.
105. VanCott T.C., et al. Lack of induction of antibodies specific for conserved, discontinuous epitopes of H0IV-1 envelope glycoprotein by candidate AIDS vaccines. J. Immunol. 155:1995;4100-4110.
106. Hifumi E., et al. Elimination of ingredients effect to improve the detection of anti HIV-1 p24 antibody in human serum using SPR apparatus. Anal. Sci. 18:2002;863-867.
107. Lescar J., et al. Preliminary crystallographic studies of an anti-HIV-1 protease antibody that inhibits enzyme activity. Protein Sci. 5:1996;966-968.